FLAP is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes. It is an integral protein within the nuclear membrane. FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consist of 4 transmembrane alpha helices, but they are found in 3’s( trimer) forming a barrel. The barrel is about 60 A high and 36 A wide.
Gene polymorphisms in FLAP are suspected of playing a role in Alzheimer's disease. Leukotrienes, which need the FLAP protein to be made, have an established pathological role in allergic and respiratory diseases. Animal and human genetic evidence suggests they may also have an important role in atherosclerosis, myocardial infarction, and stroke. The structure of FLAP provides a tool for the development of novel therapies for respiratory and cardiovascular diseases and for the design of focused experiments to probe the cell biology of FLAP and its role in leukotriene biosynthesis.
^Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA (May 1991). "Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP)". J. Biol. Chem.266 (13): 8511–6. PMID1673682.
^Yandava CN, Kennedy BP, Pillari A, Duncan AM, Drazen JM (February 1999). "Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12". Genomics56 (1): 131–3. doi:10.1006/geno.1998.5651. PMID10036194.
^Manev H, Manev R (2006). "5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease". Med Hypotheses66 (3): 501–3. doi:10.1016/j.mehy.2005.09.031. PMID16278051.
Bevan S, Lorenz MW, Sitzer M, Markus HS (2009). "Genetic variation in the leukotriene pathway and carotid intima-media thickness: a 2-stage replication study.". Stroke40 (3): 696–701. doi:10.1161/STROKEAHA.108.525733. PMID19131661.
Yoshida T, Kato K, Yokoi K et al. (2009). "Association of genetic variants with chronic kidney disease in Japanese individuals with type 2 diabetes mellitus.". Int. J. Mol. Med.23 (4): 529–37. doi:10.3892/ijmm_00000161. PMID19288030.
He YL, Zhu M, Jin XP, Zhou YL (2009). "[Relationship of polymorphism of SG13S114A/T in ALOX5AP gene with atherosclerotic cerebral infarction]". Zhejiang Da Xue Xue Bao Yi Xue Ban38 (6): 630–3. PMID20014490.
York TP, Vargas-Irwin C, Anderson WH, van den Oord EJ (2009). "Asthma pharmacogenetic study using finite mixture models to handle drug-response heterogeneity.". Pharmacogenomics10 (5): 753–67. doi:10.2217/pgs.09.19. PMID19450127.
Bizzintino JA, Khoo SK, Zhang G et al. (2009). "Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma.". Prostaglandins Leukot. Essent. Fatty Acids81 (1): 9–15. doi:10.1016/j.plefa.2009.05.022. PMID19524426.
Zintzaras E, Rodopoulou P, Sakellaridis N (2009). "Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE gene-disease association review and meta-analysis.". Am. J. Epidemiol.169 (5): 523–32. doi:10.1093/aje/kwn368. PMID19126581.
van der Net JB, Janssens AC, Defesche JC et al. (2009). "Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia.". Am. J. Cardiol.103 (3): 375–80. doi:10.1016/j.amjcard.2008.09.093. PMID19166692.
Liu J, Sun K, Bai Y et al. (2009). "Association of three-gene interaction among MTHFR, ALOX5AP and NOTCH3 with thrombotic stroke: a multicenter case-control study.". Hum. Genet.125 (5-6): 649–56. doi:10.1007/s00439-009-0659-0. PMID19373490.
Tsai AK, Li N, Hanson NQ et al. (2009). "Associations of genetic polymorphisms of arachidonate 5-lipoxygenase-activating protein with risk of coronary artery disease in a European-American population.". Atherosclerosis207 (2): 487–91. doi:10.1016/j.atherosclerosis.2009.06.018. PMID19596330.
Strid T, Svartz J, Franck N et al. (2009). "Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein.". Biochem. Biophys. Res. Commun.381 (4): 518–22. doi:10.1016/j.bbrc.2009.02.074. PMID19233132.
Oosterveer DM, Versmissen J, Yazdanpanah M et al. (2009). "5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.". Atherosclerosis206 (1): 223–7. doi:10.1016/j.atherosclerosis.2009.02.019. PMID19361804.